The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial
Open accessAbstract
BACKGROUND: Patients with severe asthma are at increased risk of exacerbations and lower respiratory tract infections (LRTI). Severe asthma is heterogeneous, encompassing eosinophilic and non-eosinophilic (mainly neutrophilic) phenotypes. Patients with neutropilic airway diseases may benefit from macrolides. METHODS: We performed a randomised double-blind placebo-controlled trial in subjects with exacerbation-prone severe asthma. Subjects received low-dose azithromycin (n=55) or placebo (n=54) as add-on treatment to combination therapy of inhaled corticosteroids and long-acting β2 agonists for 6 months. The primary outcome was the rate of severe exacerbations and LRTI requiring treatment with antibiotics during the 26-week treatment phase. Secondary efficacy outcomes included lung function and scores on the Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ). RESULTS: The rate of primary endpoints (PEPs) during 6 months was not significantly different between the two treatment groups: 0.75 PEPs (95% CI 0.55 to 1.01) per subject in the azithromycin group versus 0.81 PEPs (95% CI 0.61 to 1.09) in the placebo group (p=0.682). In a predefined subgroup analysis according to the inflammatory phenotype, azithromycin was associated with a significantly lower PEP rate than placebo in subjects with non-eosinophilic severe asthma (blood eosinophilia ≤200/µl): 0.44 PEPs (95% CI 0.25 to 0.78) versus 1.03 PEPs (95% CI 0.72 to 1.48) (p=0.013). Azithromycin significantly improved the AQLQ score but there were no significant between-group differences in the ACQ score or lung function. Azithromycin was well tolerated, but was associated with increased oropharyngeal carriage of macrolide-resistant streptococci. CONCLUSIONS: Azithromycin did not reduce the rate of severe exacerbations and LRTI in patients with severe asthma. However, the significant reduction in the PEP rate in azithromycin-treated patients with non-eosinophilic severe asthma warrants further study. CLINICALTRIALS.GOV NUMBER: NCT00760838.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G., Leigh, M. W., Lundberg, J. O., Olin, A.-C., Plummer, A. L., & Taylor, D. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.9120-11st · Cited by 2,539
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Asthma: defining of the persistent adult phenotypes
Wenzel, S. E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69290-8 · Cited by 1,043
Azithromycin and the Risk of Cardiovascular Death
Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1003833 · Cited by 954
Green, R. H. (2002) · Thorax · doi:10.1136/thorax.57.10.875 · Cited by 848
New insights into the immunology of chronic obstructive pulmonary disease
Brusselle, G. G., Joos, G. F., & Bracke, K. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60988-4 · Cited by 776
Self-citation
Cited by
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Self-citationManagement of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00588-2019 · Cited by 629
Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis
Moore, W. C., Hastie, A. T., Li, X., Li, H., Busse, W. W., Jarjour, N. N., Wenzel, S. E., Peters, S. P., Meyers, D. A., & Bleecker, E. R. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.011 · Cited by 600
Cellular and molecular mechanisms of asthma and COPD
Barnes, P. J. (2017) · Clinical Science · doi:10.1042/cs20160487 · Cited by 511
Metadata
- Authors
- Brusselle, G. G., VanderStichele, C., Jordens, P., Deman, R., Slabbynck, H., Ringoet, V., Verleden, G., Demedts, I. K., Verhamme, K., Delporte, A., Demeyere, B., Claeys, G., Boelens, J., Padalko, E., Verschakelen, J., Van Maele, G., Deschepper, E., & Joos, G. F. P.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2013-01-03
- Volume
- 68
- Issue
- 4
- Pages
- 322-329
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W2146887625
- Cited by
- 477
- References
- 31
- FWCI
- 31.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. https://app.cochat.ai/papers/10.1136/thoraxjnl-2012-202698
- The paper
- Brusselle, G. G., VanderStichele, C., Jordens, P., Deman, R., Slabbynck, H., Ringoet, V., Verleden, G., Demedts, I. K., Verhamme, K., Delporte, A., Demeyere, B., Claeys, G., Boelens, J., Padalko, E., Verschakelen, J., Van Maele, G., Deschepper, E., & Joos, G. F. P. (2013). Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. https://doi.org/10.1136/thoraxjnl-2012-202698
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.